Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment
Ask Bio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy’s effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure.